Anand P. Chokkalingam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anand P. Chokkalingam has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ann W. Hsing
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
1 shared publicationF.K. Mostofi
Armed Forces Institute of Pathology, Washington, District of Columbia
1 shared publicationFrank Z. Stanczyk
Departments of Obstetrics and Gynecology, and Preventive Medicine, Keck School of Medicine, University of Southern California, California
1 shared publicationIsabell A. Sesterhenn
Armed Forces Institute of Pathology, Washington, District of Columbia
1 shared publicationJie Deng
Shanghai Cancer Institute, Shanghai, China
1 shared publicationJoseph F. Fraumeni
1 shared publication
Latest Publications
- 23 May 2002
- Published by Wiley in The Prostate
- Vol. 52 (2) , 98-105
Insulin‐like growth factors and risk of benign prostatic hyperplasia†
BACKGROUND: Insulin‐like growth factors (IGFs) have potent growth mitogenic and anti‐apoptotic effects on prostate tissue, whereas IGF binding proteins (IGFBPs) inhibit growth of prostatic tissue. The IGF axis has been implicated in prostate cancer risk, but its role in benign prostatic hyperplasia (BPH) is unclear.METHODS: Plasma levels of IGF‐I, IGF‐II, IGFBP‐1, and IGFBP‐3 were determined from the fasting bloods of 206 BPH cases admitted for treatment and 306 randomly selected population controls in Shanghai, China.RESULTS: Relative to the lowest tertile, men in the highest tertile of IGF‐I levels had a significantly elevated risk of BPH (odds ratio [OR] = 2.80, 95% confidence interval [95% CI] = 1.60–4.92; Ptrend < 0.001). Results for IGF‐I were more pronounced after adjustment for serum androgens. In contrast, men in the highest IGFBP‐3 tertile had a significantly reduced risk (OR = 0.40; 95% CI = 0.23–0.69; Ptrend < 0.001). No associations of BPH with IGF‐II and IGFBP‐1 were observed.CONCLUSION: As has been previously observed for prostate cancer, we found that IGF‐I and IGFBP‐3 are associated with BPH risk in China. Further investigation is needed to elucidate the role of the IGF axis in BPH etiology. Prostate 52: 98–105, 2002. Published 2002 Wiley‐Liss, Inc.
- 23 May 2002
- Published by Wiley in The Prostate
- Vol. 52 (2) , 98-105
Insulin‐like growth factors and risk of benign prostatic hyperplasia†
BACKGROUND: Insulin‐like growth factors (IGFs) have potent growth mitogenic and anti‐apoptotic effects on prostate tissue, whereas IGF binding proteins (IGFBPs) inhibit growth of prostatic tissue. The IGF axis has been implicated in prostate cancer risk, but its role in benign prostatic hyperplasia (BPH) is unclear.METHODS: Plasma levels of IGF‐I, IGF‐II, IGFBP‐1, and IGFBP‐3 were determined from the fasting bloods of 206 BPH cases admitted for treatment and 306 randomly selected population controls in Shanghai, China.RESULTS: Relative to the lowest tertile, men in the highest tertile of IGF‐I levels had a significantly elevated risk of BPH (odds ratio [OR] = 2.80, 95% confidence interval [95% CI] = 1.60–4.92; Ptrend < 0.001). Results for IGF‐I were more pronounced after adjustment for serum androgens. In contrast, men in the highest IGFBP‐3 tertile had a significantly reduced risk (OR = 0.40; 95% CI = 0.23–0.69; Ptrend < 0.001). No associations of BPH with IGF‐II and IGFBP‐1 were observed.CONCLUSION: As has been previously observed for prostate cancer, we found that IGF‐I and IGFBP‐3 are associated with BPH risk in China. Further investigation is needed to elucidate the role of the IGF axis in BPH etiology. Prostate 52: 98–105, 2002. Published 2002 Wiley‐Liss, Inc.